Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti‐inflammatory effects in mdx mice with Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti‐inflammatory effects in mdx mice with Duchenne muscular dystrophy

Published:2017-08-10 Issue:12 Volume:31 Page:5307-5320
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Nio Yasunori¹,Tanaka Masayuki²,Hirozane Yoshihiko³,Muraki Yo¹,Okawara Mitsugi¹,Hazama Masatoshi¹,Matsuo Takanori¹

Affiliation:

1. Extra Value Generation and General Medicine Drug Discovery UnitTakeda Pharmaceutical Company Limited Fujisawa Japan

2. Inflammation Drug Discovery UnitTakeda Pharmaceutical Company Limited Fujisawa Japan

3. Biomolecular Research LaboratoriesPharmaceutical Research DivisionTakeda Pharmaceutical Company Limited Fujisawa Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201700249R

Reference55 articles.

1. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

2. Resveratrol attenuates hyperoxia-induced oxidative stress, inflammation and fibrosis and suppresses Wnt/β-catenin signalling in lungs of neonatal rats

3. SIRT1 regulates hepatocyte lipid metabolism through activating AMP‐activated protein kinase;Hou X.;Biol. Chem.,2008

4. SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function

5. Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure;Cellular and Molecular Biology;2023-03-31

2. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis;European Respiratory Review;2023-02-21

3. Update on anti-fibrotic pharmacotherapies in skeletal muscle disease;Current Opinion in Pharmacology;2023-02

4. Heart-on-a-chip platforms and biosensor integration for disease modeling and phenotypic drug screening;Biosensors and Bioelectronics;2023-01

5. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules;Frontiers in Pharmacology;2022-11-24